会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Chimeric adenoviruses
    • 嵌合腺病毒
    • US07749493B2
    • 2010-07-06
    • US11207626
    • 2005-08-18
    • Menzo HavengaRonald VogelsAbraham Bout
    • Menzo HavengaRonald VogelsAbraham Bout
    • A61K48/00C12N15/00C12N15/09C12N15/11C12N15/34
    • C12N15/86C07K14/005C12N2710/10322C12N2710/10344C12N2760/20134
    • The present invention provides methods and vector systems for the generation of chimeric recombinant adenoviruses. These hybrid adenoviruses contain a genome that is derived from different adenovirus serotypes. In particular, novel hybrid adenoviruses are disclosed with improved properties for gene therapy purposes. These properties include: a decreased sensitivity towards neutralizing antibodies, a modified host range, a change in the titer to which adenovirus can be grown, the ability to escape trapping in the liver upon in vivo systemic delivery, and absence or decreased infection of antigen presenting cells (APC) of the immune system, such as macrophages or dendritic cells. These chimeric adenoviruses thus represent improved tools for gene therapy and vaccination since they overcome the limitations observed with the currently used serotype subgroup C adenoviruses.
    • 本发明提供用于产生嵌合重组腺病毒的方法和载体系统。 这些杂合腺病毒含有衍生自不同腺病毒血清型的基因组。 特别地,公开了具有改进的用于基因治疗目的的性质的新型杂合腺病毒。 这些性质包括:对中和抗体的降低的敏感性,修饰的宿主范围,可以生长腺病毒的滴度的变化,在体内全身递送时逃避捕获在肝脏中的能力,以及抗原呈递的不存在或减少的感染 免疫系统的细胞(APC),例如巨噬细胞或树突状细胞。 因此,这些嵌合腺病毒代表了用于基因治疗和疫苗接种的改进工具,因为它们克服了目前使用的血清型亚型C腺病毒所观察到的限制。
    • 8. 发明申请
    • Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
    • 为平滑肌细胞和/或内皮细胞提供组织嗜性的基因递送载体
    • US20050169891A1
    • 2005-08-04
    • US11018669
    • 2004-12-20
    • Ronald VogelsMenzo HavengaAbraham Bout
    • Ronald VogelsMenzo HavengaAbraham Bout
    • A61K38/00A61K48/00C07K14/075C12N15/861
    • C07K14/005A61K38/00A61K48/00C07K2319/00C12N15/86C12N2710/10322C12N2710/10343C12N2710/10345C12N2810/6018
    • A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragments from at least two different viruses, such as two different adenoviruses, including adenovirus of subgroup C or subgroup B (for example, adenovirus 16). The protein fragments can comprise a tissue tropism-determining fragment of a fiber protein derived from a subgroup B adenovirus. Also, cells for producing such gene delivery vehicles and pharmaceutical compositions containing these gene delivery vehicles are provided. Further, a method is disclosed for delivering nucleic acid to cells such as smooth muscle cells and/or endothelial cells which involves administering to the cells an adenovirus capsid having proteins from at least two different adenoviruses and wherein at least a tissue tropism-determining fragment of a fiber protein is derived from a subgroup B adenovirus. Particular constructs are also disclosed.
    • 具有至少一种选自平滑肌细胞,内皮细胞和/或肝细胞的细胞的组织嗜性的基因递送载体。 组织向性通常由病毒衣壳提供,例如包含来自至少两种不同病毒的蛋白质片段的病毒衣壳,例如两种不同的腺病毒,包括亚组C或亚组B的腺病毒(例如,腺病毒16)。 蛋白质片段可以包含衍生自亚组B腺病毒的纤维蛋白质的组织向性决定片段。 此外,提供了用于产生这种基因递送载体的细胞和含有这些基因递送载体的药物组合物。 此外,公开了一种用于将核酸递送至诸如平滑肌细胞和/或内皮细胞的细胞的方法,其涉及向细胞施用具有来自至少两种不同腺病毒的蛋白质的腺病毒衣壳,并且其中至少一种组织向性确定片段 纤维蛋白源自B亚型腺病毒亚组。 还公开了特定的构建体。